Table 6 Association between IL-10 and TNFα genotypes and response to antimalarial treatment
From: Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs
Genotype | Healthy controls n (%) | SLE patients | Univariate analysis | Multivariate analysisa | |||
|---|---|---|---|---|---|---|---|
Good responders to antimalarials n (%) | Others n (%) | OR (95% CI) | p | OR (95% CI) | p | ||
-1,082 IL-10 | |||||||
Low (AA/AG) | 292 (85.1) | 34 (85.0) | 119 (78.8) | Referent | Referent | ||
High (GG) | 51 (14.9) | 6 (15.0) | 32 (21.2) | 0.66 (0.25–1.70) | 0.386 | 0.59 (0.20–1.78) | 0.354 |
-308 TNFα | |||||||
Low (GG) | 265 (77.3) | 17 (42.5) | 95 (62.5) | Referent | Referent | ||
High (AA/GA) | 78 (22.7) | 23 (57.5) | 57 (37.5) | 2.25 (1.11–4.58) | 0.024 | 2.67 (1.20–5.97) | 0.016 |
Combined IL-10/TNFα | |||||||
Low/Low | 224 (65.3) | 12 (30.0) | 75 (49.7) | Referent | Referent | ||
Low/High | 68 (19.8) | 22 (55.0) | 44 (29.1) | 3.13 (1.41–6.92) | 0.005 | 4.20 (1.66–10.63) | 0.002 |
High/Low | 41 (12.0) | 5 (12.5) | 19 (12.6) | 1.64 (0.52–5.24) | 0.400 | 1.77 (0.47–6.63) | 0.397 |
High/High | 10 (2.9) | 1 (2.5) | 13 (8.6) | 0.48 (0.06–4.02) | 0.499 | 0.43 (0.04–4.21) | 0.472 |
Trend test | 0.021 | 0.011 | |||||